Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 15, 2018Journal of Clinical OncologyOpen Access

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712—A Randomized Phase II Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJohn J. CoenNorthern Sydney Local Health DistrictPZPeixin ZhangChina University of Mining and TechnologyPSPhilip J. SaylorHarvard University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Coen et al. (2018) studied this question.

synapsesocial.com/papers/6a1eeca33a6d7bb4f3c8de6dhttps://doi.org/10.1200/jco.18.00537
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Proportional Hazards Model for the Subdistribution of a Competing Risk1999 · 13,956 citations
  2. 2THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL1934 · 4,911 citations
  3. 3Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients2001 · 3,564 citations
  4. 4Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 02332014 · 463 citations
  5. 5Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer2011 · 186 citations